AAM
CYTK icon

AMI Asset Management’s Cytokinetics CYTK Stock Holding History

AMI Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$977K Buy
14,816
+536
+4% +$34.1K 0.06% 57
2025
Q4 		$907K Sell
14,280
-1,003
-7% -$62.4K 0.05% 62
2025
Q3 		$840K Buy
+15,283
New +$630K 0.05% 67

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AMI Asset Management's CYTK Position: Q1 2026 in Review

AMI Asset Management increased its Cytokinetics (CYTK) stake by 3.8% in Q1 2026, buying an estimated $34.1K and bringing the position to 14,816 shares worth $977K. The position accounts for 0.06% of the portfolio, ranked #57.

AMI Asset Management first reported a position in CYTK in Q3 2025 and has held it in 3 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • AMI Asset Management held 14,816 shares of Cytokinetics worth $977K as of Q1 2026.
  • AMI Asset Management bought 536 Cytokinetics shares in Q1 2026, an estimated $34.1K.
  • Cytokinetics made up 0.06% of AMI Asset Management's portfolio in Q1 2026, its #57 holding.
  • AMI Asset Management first reported a position in Cytokinetics in Q3 2025 and has held it in 3 quarters since.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on AMI Asset Management's 13F filing for Q1 2026, filed 23 Apr 2026.